Dr. Feng Wang is currently a professor, assistant president and director in the Department of Medical Oncology at Sun Yat-Sen University Cancer Center, Guangzhou, China. She has extensive experience and expertise in the field of Gastrointestinal Medical Oncology and translation research in gastrointestinal cancers. Dr Wang sees more than thousands of patients with gastrointestinal cancers annually and has initiated or participated in many investigators initiated and NMPA approved clinical trials. She presides over a number of research programs including the international (regional) cooperation and exchange program, and general program from the national natural science foundation of China, the Doctoral Program of Higher Education of China, and has participated in several international cooperation, national and provincial level projects. Dr. Wang has published over 105 peer-reviewed articles, including some first author or corresponding author papers in renowned journals such as Nature Medicine, Cancer Cell, Journal of Clinical Oncology, JAMA Oncology, Annals of Oncology, The Lancet Gastroenterology and Hepatology, Gut, etc and has been invited to present her research results at ASCO, AACR, CSCO, ESMO, JSCO, Nature Conference, Chinese Congress of Oncology and other international conferences. She is a member of the Guidelines Expert group that developed the European Society for Medical Oncology (ESMO) Pan-Asian Gastric Cancer Guidelines; Developed the CSCO Colorectal Cancer Guidelines as Secretary-General of the Guidelines Expert Group. She was awarded many prizes including the Second Prize of National Science and Technology Progress Award, First Prize of Chinese Medical Science and Technology Award, the First Prize of Guangdong Province Science and Technology Progress Award, "Important Medical Progress 2022" Award of Chinese Academy of Medical Sciences, Guangdong Youth May Fourth Medal etc. She holds many academic posts, including the Vice Chairman of Youth Council of China Anti-Cancer Association, vice director of Youth Committee of Professional Committee of Tumor Targeted Therapy, Chinese anti-cancer association and a Chairing Committee member of Chinese Society of Clinical Oncology etc. 

Sep 2008-Jun 2012
UT M.D. Anderson Cancer Center, PhD 

Jul 2008-Sep 2005
Sun Yat-sen University Cancer Center, MS

Sep 2000-Jul 2005
Jiangxi Medical College, Bachelor of Medicine

Selected publications

1. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Yuan SQ, Nie RC, Jin Y, Liang CC, Li YF, Jian R, Sun XW, Chen YB, Guan WL, Wang ZX, Qiu HB, Wang W, Chen S, Zhang DS, Ling YH, Xi SY, Cai MY, Huang CY, Yang QX, Liu ZM, Guan YX, Chen YM, Li JB, Tang XW, Peng JS, Zhou ZW, Xu RH*, Wang F*. Nat Med. 2024.

2. Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study. Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, Quan TT, Xi SY, Zhang HZ, Pan ZZ, Wang F*, Xu RH*. Lancet Gastroenterol Hepatol. 2023.

3. An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma. Chen YX, Wang ZX, Jin Y, Zhao Q, Liu ZX, Zuo ZX, Ju HQ, Cui C, Yao J, Zhang Y, Li M, Feng J, Tian L, Xia XJ, Feng H, Yao S, Wang FH, Li YH, Wang F*, Xu RH*. Cancer Cell. 2023.

4. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Yuan SQ, Nie RC, Huang YS, Chen YB, Wang SY, Sun XW, Li YF, Liu ZK, Chen YX, Yao YC, Xu Y, Qiu HB, Liang Y, Wang W, Liu ZX, Zhao Q, Xu RH*, Zhou ZW*, Wang F*. Cancer Commun (Lond). 2023. 

5. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. Wu HX, Pan YQ, He Y, Wang ZX, Guan WL, Chen YX, Yao YC, Shao NY, Xu RH*, Wang F*. J Clin Oncol. 2023.

6. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH*, Wang F*. Cancer Cell. 2022.

7. Impact of mismatch repair or microsatellite status on the prognosis and efficacy to chemotherapy in metastatic colorectal cancer patients: A bi-institutional, propensity score-matched study. Yao YC, Jin Y, Lei XF, Wang ZX, Zhang DS, Wang FH, Li YH, Xu RH*, Wang F*. J Cancer. 2022.

8. A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer. Wang F, He MM, Xiao J, Zhang YQ, Yuan XL, Fang WJ, Zhang Y, Wang W, Hu XH, Ma ZG, Yao YC, Zhuang ZX, Zhou FX, Ying JE, Yuan Y, Zou QF, Guo ZQ, Wu XY, Jin Y, Mai ZJ, Wang ZQ, Qiu H, Guo Y, Shi SM, Chen SZ, Luo HY, Zhang DS, Wang FH, Li YH, Xu RH*. Clin Cancer Res. 2022.

9. Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer. Zhao Q, Wang F*, Chen YX, Chen S, Yao YC, Zeng ZL, Jiang TJ, Wang YN, Wu CY, Jing Y, Huang YS, Zhang J, Wang ZX, He MM, Pu HY, Mai ZJ, Wu QN, Long R, Zhang X, Huang T, Xu M, Qiu MZ, Luo HY, Li YH, Zhang DS, Jia WH, Chen G, Ding PR, Li LR, Lu ZH, Pan ZZ, Xu RH*. Nat Commun. 2022.

10. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Wang F*, Huang YS, Wu HX, Wang ZX, Jin Y, Yao YC, Chen YX, Zhao Q, Chen S, He MM, Luo HY, Qiu MZ, Wang DS, Wang FH, Xu M, Li YH, Xu RH*. Gut. 2022.

11. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Chen G, Peng J, Xiao Q, Wu HX, Wu X, Wang F, Li L, Ding P, Zhao Q, Li Y, Wang D, Shao Y, Bao H, Pan Z, Ding KF, Cai S, Wang F*, Xu RH*. J Hematol Oncol. 2021.

12. POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. Chen YX, Wang ZX, Yuan SQ, Jiang TJ, Huang YS, Xu RH*, Wang F*, Zhao Q*. Clin Transl Med. 2021.

13. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, Lv ZD, Wang DS, Li YH, Zhang DS, Xu RH*. Cell Rep Med. 2021.

14. Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer. Wei XL, Xu JY, Wang DS, Chen DL, Ren C, Li JN, Wang F*, Wang FH*, Xu RH*. Ther Adv Med Oncol. 2021.

15. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH*, Zhang DS*. Mol Cancer. 2020.

16. Germline mutational profile of Chinese patients under 70 years old with colorectal cancer. Jiang TJ, Wang F, Wang YN, Hu JJ, Ding PR, Lin JZ, Pan ZZ, Chen G, Shao JY, Xu RH, Zhao Q, Wang F*. Cancer Commun (Lond). 2020.

17. Expert opinions on immunotherapy for patients with colorectal cancer. Wang F, Wang ZX, Chen G, Luo HY, Zhang DS, Qiu MZ, Wang DS, Pan ZZ, Shen L, Li J, Zhang SZ, Xu RH*. Cancer Commun (Lond). 2020.

18. AMPKα1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation. Wang YN, Lu YX, Liu J, Jin Y, Bi HC, Zhao Q, Liu ZX, Li YQ, Hu JJ, Sheng H, Jiang YM, Zhang C, Tian F, Chen Y, Pan ZZ, Chen G, Zeng ZL, Liu KY, Ogasawara M, Yun JP, Ju HQ, Feng JX, Xie D, Gao S, Jia WH, Kopetz S, Xu RH, Wang F*. Oncogene. 2020.

19. Inhibition of fatty acid catabolism augments the efficacy of oxaliplatin-based chemotherapy in gastrointestinal cancers. Wang Y, Lu JH, Wang F, Wang YN, He MM, Wu QN, Lu YX, Yu HE, Chen ZH, Zhao Q, Liu J, Chen YX, Wang DS, Sheng H, Liu ZX, Zeng ZL, Xu RH*, Ju HQ*. Cancer Lett. 2020.

20. Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. Wang F, Liu TS, Yuan XL, Luo HY, Gu KS, Yuan Y, Deng YH, Xu JM, Bai YX, Wang Y, Liao WJ, Zhang HL, Bi F, Wang BM, Zhuang ZX, Jiang TJ, Xu RH*. Am J Cancer Res. 2020.

21. Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial. Ren C, Mai ZJ, Jin Y, He MM, Wang ZQ, Luo HY, Zhang DS, Wu CY, Wang F*, Xu RH*. Am J Cancer Res. 2020.

22. Systematic analysis of the transcriptome in small-cell carcinoma of the oesophagus reveals its immune microenvironment. Zhao Q, Chen YX, Wu QN, Zhang C, Liu M, Wang YN, Feng YF, Hu JJ, Fu JH, Yang H, Qi JJ, Wang ZX, Lu YX, Sheng H, Liu ZX, Zuo ZX, Zheng J, Yun JP, Bei JX, Jia WH, Lin DX, Xu RH*, Wang F*. Clin Transl Immunology. 2020.

23. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. Liu F, Ren C, Jin Y, Xi S, He C, Wang F, Wang Z, Xu RH, Wang F*. Virchows Arch. 2020.

24. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH*. JAMA Oncology. 2019.

25. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH*. Annals of Oncology. 2019.

26. The genomic landscape of small cell carcinoma of the esophagus. Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX, Xu RH*. Cell Research. 2018.